trending Market Intelligence /marketintelligence/en/news-insights/trending/sWDH0HIlvQbS5EdhGDYhRg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Dynavax prices offering; FDA extends hepatitis B vaccine review deadline

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Dynavax prices offering; FDA extends hepatitis B vaccine review deadline

Dynavax Technologies Corp. priced its offering of 5 million common shares at $15 per share, for expected gross proceeds of about $75 million.

The company granted the underwriters a 30-day option to buy up to 750,000 additional shares of its common stock.

The offering is expected to close on or around August 15, 2017, subject to customary closing conditions.

Cowen, RBC Capital Markets and William Blair are acting as joint book-running managers for the offering, with Cantor Fitzgerald & Co. as lead manager.

Separately, Dynavax said in an SEC filing that the U.S. Food and Drug Administration notified the company that its response to the FDA's request for additional information regarding Dynavax's proposed post-marketing study for Heplisav-B is considered a major amendment to the company's biologics license application.

Further, the Heplisav-B Prescription Drug User Fee Act date has been extended by three months to Nov. 9.